TB-500 (Thymosin Beta-4)

Name: TB-500 (Thymosin Beta-4)
SKU: 214412-1-1-5-1-1
Availability: InStock

Price range: $34.99 through $65.00

TB-500 is a synthetic form of Thymosin Beta-4 known for its powerful role in tissue regeneration, cell migration, and wound healing. It is widely researched for soft tissue repair, inflammation reduction, and promoting angiogenesis (new blood vessel formation).

Select Mg

Clear

SKU: 214412-1-1-5-1-1 Category: Muscle Growth & Performance

High-Level Summary

TB-500 is a synthetic version of a naturally occurring peptide known as Thymosin Beta-4. It is recognized for its role in tissue regeneration, cell migration, and wound healing. TB-500 is widely studied in experimental models of soft tissue repair, inflammation reduction, and cardiovascular healing. Its ability to promote cellular remodeling and increase angiogenesis makes it a valuable research compound for regeneration-focused applications.

– Form: Lyophilized peptide
– Purity: >99%
– Origin: Manufactured and tested in the USA
– Certifications: Certificate of Analysis (COA) included with every order

Mechanism of Action (MOA)

TB-500 mimics the effects of Thymosin Beta-4 by:
– Enhancing cell migration and differentiation
– Promoting angiogenesis (formation of new blood vessels)
– Reducing inflammatory responses at injury sites
– Supporting actin binding and cytoskeletal remodeling

Research Applications

– Wound healing and soft tissue regeneration
– Muscle and ligament recovery studies
– Inflammation modulation and scar reduction
– Cardiovascular tissue healing models
– Ophthalmic and corneal repair studies

Key Benefits for Research

– Versatile applications across organ systems
– Rapid onset of action in tissue injury models
– Synergistic potential with other regenerative peptides
– Favorable stability and low immunogenicity

Certificate of Purity & Testing

Each vial is:
– Produced in a GMP-compliant U.S. facility
– Supplied with a Certificate of Analysis (COA)
– Tested via HPLC and mass spectrometry
– Shipped securely from the USA

Formulation & Dosage Info

– Contents: 5mg or 10mg of lyophilized TB-500 peptide
– Appearance: White/off-white powder
– Solubility: Sterile bacteriostatic water recommended
– Storage: Store lyophilized powder at -20°C; stable for up to 30 days post-reconstitution if refrigerated
*For laboratory research use only. Not intended for human or veterinary use.*

Legal & Compliance Notices

– Sold strictly for research purposes
– Not for human consumption or diagnostic use
– Researchers must adhere to applicable legal and institutional safety protocols

What is TB-500?

TB-500 is the synthetic version of a naturally occurring peptide known as Thymosin Beta-4. It is widely researched for its role in cellular regeneration, tissue repair, angiogenesis, and inflammation modulation.

What is the mechanism of action of TB-500?

TB-500 promotes cell migration and angiogenesis by upregulating actin-binding proteins. It plays a crucial role in tissue healing by supporting new blood vessel formation, reducing inflammation, and improving flexibility at the site of injury in research models.

What form does TB-500 come in?

American Peptides supplies TB-500 as a lyophilized powder in sterile, research-grade vials. Our compounds are made in the USA and undergo rigorous lab testing to ensure consistency, sterility, and purity.

How should TB-500 be stored?

Store the lyophilized vial at -20°C in a dry, light-protected environment. Once reconstituted, keep the solution refrigerated at 2–8°C and use within your lab’s recommended timeframe to maintain integrity.

What is the purity of your TB-500?

Each vial of TB-500 is ≥98% pure, confirmed through HPLC and Mass Spectrometry. A batch-specific Certificate of Analysis (COA) is included with every purchase, so your lab has complete transparency on quality.

Do you offer cold-chain shipping for TB-500?

Yes. While TB-500 is stable during shipping in our standard packaging, cold-chain shipping is available on request for sensitive applications or bulk research orders.

Can TB-500 be used with other peptides?

In preclinical settings, TB-500 is sometimes studied alongside other healing peptides such as BPC-157 or growth factors. All use should comply with approved lab protocols and sterile handling procedures.

How do I get a Certificate of Analysis?

Visit our Lab Test Results page, choose TB-500 from the dropdown menu, and enter your email. We’ll send you the full COA for the batch you’ve ordered.

Why choose American Peptides for TB-500?

We guarantee ≥98% purity, verified lab testing, and U.S.-based manufacturing. Every order includes a COA, and our Price Match Guarantee ensures you receive the best value for your research budget—if you find comparable quality for less, we’ll match it.

TB-500 (5 mg & 10 mg Vial) Dosage Protocol

Quickstart Highlights

TB‑500 is a synthetic peptide fragment corresponding to the active region of thymosin beta‑4 (Tβ4), a naturally occurring 43‑amino‑acid protein involved in tissue repair and regeneration^[1]^[2]. This educational protocol presents a once‑daily subcutaneous approach using practical dilutions for accurate insulin‑syringe measurements in research settings.

5 mg Vial

Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
Typical daily range: 500–1000 mcg once daily (gradual titration recommended).
Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U‑100 insulin syringe.

10 mg Vial

Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
Typical daily range: 500–1000 mcg once daily (gradual titration recommended).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U‑100 insulin syringe.

Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach

5 mg Vial (3 mL = ~1.67 mg/mL)

Phase	Daily Dose (mcg)	Units (per injection) (mL)
Weeks 1–2	500 mcg	30 units (0.30 mL)
Weeks 3–4	600 mcg	36 units (0.36 mL)
Weeks 5–8	750 mcg	45 units (0.45 mL)
Weeks 9–12	1000 mcg	60 units (0.60 mL)

10 mg Vial (3 mL = ~3.33 mg/mL)

Phase	Daily Dose (mcg)	Units (per injection) (mL)
Weeks 1–2	500 mcg	15 units (0.15 mL)
Weeks 3–4	600 mcg	18 units (0.18 mL)
Weeks 5–8	750 mcg	23 units (0.23 mL)
Weeks 9–12	1000 mcg	30 units (0.30 mL)

Frequency: Inject once daily subcutaneously. These schedules use the largest practical dilution (3.0 mL) to keep per‑injection units in a comfortable range for accurate measurement. Total weekly dose averages ~5 mg, consistent with research protocols^[3]^[4].

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label with date and concentration; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

5 mg Vials (TB‑500, 5 mg each)

8 weeks ≈ 8 vials
12 weeks ≈ 12 vials
16 weeks ≈ 16 vials

10 mg Vials (TB‑500, 10 mg each)

8 weeks ≈ 4 vials
12 weeks ≈ 7 vials
16 weeks ≈ 10 vials

Insulin Syringes (U‑100)

Per week: 7 syringes (1/day)
8 weeks: 56 syringes
12 weeks: 84 syringes
16 weeks: 112 syringes

Bacteriostatic Water (10 mL bottles)

Use ~3.0 mL per vial for reconstitution.

5 mg protocol (8 weeks, 8 vials): 24 mL → 3 × 10 mL bottles
10 mg protocol (8 weeks, 4 vials): 12 mL → 2 × 10 mL bottles
10 mg protocol (12 weeks, 7 vials): 21 mL → 3 × 10 mL bottles

Alcohol Swabs

One for the vial stopper + one for the injection site each day.

Per week: 14 swabs (2/day)
8 weeks: 112 swabs → recommend 2 × 100‑count boxes
12 weeks: 168 swabs → recommend 2 × 100‑count boxes
16 weeks: 224 swabs → recommend 3 × 100‑count boxes

Protocol Overview

Concise summary of the once‑daily regimen.

Goal: Support tissue repair, wound healing, and angiogenesis through the active thymosin beta‑4 fragment mechanism^[5]^[6].
Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if research goals require).
Dose Range: 500–1000 mcg daily with gradual titration (~5 mg/week average).
Reconstitution: 3.0 mL per vial (1.67 mg/mL for 5mg, 3.33 mg/mL for 10mg) for accurate unit measurements.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid freeze–thaw cycles of reconstituted solution.

Dosing Protocol

Suggested daily titration approach.

Start: 500 mcg daily; increase by ~100–150 mcg every 2 weeks as tolerated.
Target: 750–1000 mcg daily by Weeks 5–12.
Frequency: Once per day (subcutaneous).
Cycle Length: 8–12 weeks; optional extension to 16 weeks based on research protocol.
Timing: Any consistent time daily; rotate injection sites systematically.

Storage Instructions

Proper storage preserves peptide quality and activity.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure^[7].
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution as freezing can denature peptides.
Allow vials to reach room temperature before opening to reduce condensation uptake.
Use reconstituted vials within 28 days when stored with bacteriostatic water preservative^[8].

Important Notes

Practical considerations for consistency and safety in research protocols.

Use new sterile insulin syringes for each injection; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and lipohypertrophy^[9].
Inject slowly; wait a few seconds before withdrawing the needle to prevent backflow.
Document daily dose, injection site, and any observations to maintain consistency.
Regulatory Note: TB‑500 is banned by WADA for athletic use and is not FDA‑approved for human administration^[10].

How This Works

TB‑500 represents the N‑terminal active fragment of thymosin beta‑4, specifically the heptapeptide sequence Ac‑LKKTETQ^[1]^[2]. This region is responsible for the actin‑binding and cell‑migration properties of the full thymosin molecule. Preclinical studies demonstrate that TB‑500 promotes angiogenesis, accelerates wound healing, and supports tissue regeneration by upregulating cell motility and blood vessel formation^[5]^[6]. Research in animal models shows enhanced collagen deposition and reduced healing time in injury sites treated with thymosin fragments^[11]. Recent metabolic studies suggest TB‑500 may act as a prodrug, cleaving to an active pentapeptide metabolite that drives biological activity^[12].

Potential Benefits & Side Effects

Observations from preclinical and veterinary literature.

Supports accelerated wound healing and tissue repair through enhanced angiogenesis and cell migration^[5]^[6].
May reduce inflammation and fibrosis indirectly via thymosin pathways observed in animal models^[11].
Generally well tolerated in veterinary studies; occasional mild injection‑site reactions (redness, tenderness) reported.
Human safety data is limited; no large‑scale clinical trials have been completed for TB‑500 specifically^[13].

Lifestyle Factors

Complementary strategies for optimal research outcomes.

Maintain adequate protein intake to support tissue repair and regeneration processes.
Combine with appropriate physical activity; avoid overtraining during injury recovery phases.
Prioritize sleep (7–9 hours) to maximize natural recovery and repair mechanisms.
Manage stress levels through evidence‑based practices to support overall healing.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources^[14]^[15].

Clean the vial stopper and skin with alcohol; allow to air dry completely.
Pinch a skinfold at the injection site; insert the needle at 45–90° into subcutaneous tissue^[14].
Do not aspirate for subcutaneous injections; inject slowly and steadily^[14].
Rotate sites systematically within approved areas (abdomen, thighs, upper arms) to avoid lipohypertrophy^[9].
Wait 5–10 seconds after injection before withdrawing needle to prevent medication leakage.

Recommended Source

We recommend American Peptides for high‑purity TB‑500 (5 mg & 10 mg).

Why American Peptides?

High‑purity peptides (≥99%) with third‑party testing and batch‑specific COAs.
Consistent quality control and ISO‑aligned handling procedures.
Reliable fulfillment with proper cold‑chain shipping to maintain peptide integrity.
Transparent documentation for research compliance.

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. TB‑500 is not approved by the FDA for human use and is for research purposes only. TB‑500 is a prohibited substance in competitive sports under WADA regulations.

References

FASEB Journal — Biological activities of thymosin β4 defined by active peptide sequences (TB‑500 fragment identification)

View Source
Journal of Chromatography A (PubMed) — Doping control analysis of TB‑500 as synthetic thymosin β4 fragment in biological samples

View Source
WADA Scientific Research — Investigation of TB‑500 metabolism, synthesis of metabolites, and detection limits

View Source
Racing Medication & Testing Consortium — Thymosin β4 regulatory bulletin (TB‑500 use in equine sports medicine)

View Source
Journal of Investigative Dermatology (PubMed) — Thymosin beta4 accelerates wound healing (preclinical wound healing model)

View Source
FASEB Journal (PubMed) — Active site mapping of thymosin β4 fragments for angiogenesis and cell migration

View Source
Verified Peptides Storage Guide — Lyophilized peptide storage best practices (temperature, humidity, light protection)

View Source
Empower Pharmacy — Bacteriostatic water injection guidelines (0.9% benzyl alcohol, multi‑dose vial stability)

View Source
NCBI Bookshelf — Best practices for subcutaneous injection (aseptic technique, site rotation)

View Source
WADA Prohibited List — TB‑500 classification as prohibited substance in competitive sports

View Source
Journal of Investigative Dermatology — Thymosin β4 wound healing mechanisms (collagen deposition, angiogenesis, granulation tissue)

View Source
Journal of Chromatography B (PubMed) — Quantification of TB‑500 metabolites and wound healing activity screening (prodrug hypothesis)

View Source